Cleo Diagnostics Ltd Stock Analysis (April 2026)

Cleo Diagnostics Ltd

ASX:COV

$ 0,59

$-0,01 (-1,67%)

0,59 $

$-0,01 (-1,67%)

End-of-day quote: 04/20/2026

Cleo Diagnostics Ltd Stock Value

The current analyst rating for ASX:COV is sf_Data Unavailable.

Cleo Diagnostics Ltd Company Info

EPS Growth 3Y

0,00%

Market Cap

$0,08 B

Long-Term Debt

$0,00 B

Quarterly earnings

05/28/2026 (E)

Dividend

$0,00

Dividend Yield

0,00%

Founded

2021

Industry

Health Care

Country

Australia

Website

Cleo Diagnostics Ltd

ISIN Number

AU0000288045

Website

http://www.cleodx.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

There are currently no price targets available for this stock.

In the last five quarters, Cleo Diagnostics Ltd’s Price Target has risen from $0,00 to $0,59 - a 100,00% increase.

Top growth stocks in the health care sector (5Y.)

What does Cleo Diagnostics Ltd do?

Cleo Diagnostics Ltd focuses on developing diagnostic solutions for various health conditions, including cancers and other significant diseases. The company emphasizes the creation and commercialization of intellectual property (IP) and strives to be at the forefront of diagnostic testing. Business Segments The company operates through research and development of diagnostic tests and related intellectual properties. The company has a singular focus on delivering diagnostic solutions that lever...

Business Segments

The company operates through research and development of diagnostic tests and related intellectual properties. The company has a singular focus on delivering diagnostic solutions that leverage advanced technological platforms. The company is engaged in R&D activities aimed at the commercialization of its proprietary diagnostic tests.

Business Strategy

The company's business strategy is centered on innovation, primarily driven by research and development (R&D) initiatives, aimed at commercializing its proprietary diagnostic solutions. The company seeks to identify unmet needs in the healthcare sector, particularly within the diagnostic domain.

A vital part of the company's strategy includes securing patents for its developed technologies and diagnostics, ensuring robust intellectual property protections that can enhance its commercial viability. By focusing on obtaining patents, the company safeguards its innovations, enabling it to capitalize potential market opportunities.

Moreover, the company aims to expedite the commercial launch of its diagnostic products by leveraging its R&D capabilities. By focusing on products that are not only innovative but also efficient in meeting specific health concerns, the company endeavors to create solutions that can be readily integrated into existing healthcare frameworks.

Products and Services

The company specializes in developing advanced diagnostic tests focused on various health conditions, particularly in oncology. The company’s range of products includes polygenic risk assessment tests for several types of cancer, which are notable for their robustness and reliability. These tests leverage methodologies to analyze genetic data, providing clinicians with vital information that aids in patient risk assessment and the development of personalized treatment plans.

The company is actively working on R&D projects that span several major diseases, such as breast cancer and colorectal cancer, with accomplishments including the commercial launch of various related tests.

The company's services are designed to not only deliver diagnostic tests but also to educate healthcare providers about their applications and interpretative value in clinical practice.

Geographical Markets Served

The company primarily operates in the Australian market.

Customers

The company serves a clientele predominantly within the Australian healthcare sector. The company engages with an array of customers, including hospitals, clinical laboratories, healthcare professionals, and research institutions that rely on accurate and reliable diagnostic tests.

Sales and Marketing

The company employs various sales and marketing strategies to promote its diagnostic products. These strategies focus primarily on building relationships within the healthcare community, targeting essential stakeholders, and ensuring that healthcare professionals are well-informed about the benefits and applications of the company’s diagnostic solutions.

The primary mode of marketing revolves around direct engagement with healthcare providers, where the company endeavors to demonstrate the efficacy and applicability of its diagnostic tests. By hosting workshops, educational seminars, and informational sessions, the company aims to foster awareness and understanding of its products within the medical community.

Additionally, the company utilizes digital marketing strategies, including an online presence and marketing campaigns tailored to attract interest. By engaging with potential customers through digital platforms, the company enhances its visibility and helps ensure that its innovative diagnostic solutions are recognized and considered within the marketplace.

History

Cleo Diagnostics Ltd was incorporated in 2021.

New support ticket

Explore

Cleo Diagnostics Ltd Stock Value

Cleo Diagnostics Ltd Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Cleo Diagnostics Ltd do?

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Cleo Diagnostics Ltd Stock Value

Cleo Diagnostics Ltd Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Cleo Diagnostics Ltd do?

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.